U.S., Aug. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07780968) titled 'Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA' on Aug. 19.
Brief Summary: The purpose of this study is to collect real-world data to describe the effectiveness and tolerability of first line zanidatamab-containing therapies and describe the subsequent lines of treatment in participants with unresectable, locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma (GEA).
Study Start Date: Oct. 01
Study Type: OBSERVATIONAL
Condition:
Esophageal Cancer
GastroEsophageal Cancer
Gastroesophageal-junction Cancer
HER2-positive Gastric Cancer
Stomach Cancer
Intervention:
DRUG: Zanidatamab...